SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is drawing attention as it consolidates around the $120$125 resistance area, with bullish traders watching for a breakout and calling for further gains. Others argue momentum is weak and warn that broader crypto-market volatility could pull SOL lower.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

A community-led push around RETIREs tokenized 401(k)/early-retirement theme, including recurring DCA campaigns, is driving attention alongside traders claims of a price and volume breakout. Bullish holders tout the community and momentum, while others point to selling pressure and warn the token may be a pump-and-dump; the retirement framing is promotional, not evidence of a conventional retirement product.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CROs price moves have renewed debate over whether Cronos app revenue and proposed buybacks and burns can support the token. Bulls see reduced supply as a catalyst, while skeptics point to the large unburned token reserve and ongoing dilution concerns as reasons gains may not hold.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Barclays downgrade to Equal Weight is drawing attention, with traders focused on concerns about Mobileyes pace of advanced driver-assistance wins and competition in China; leadership transition and speculation about Volkswagens robotaxi partner add to the uncertainty. The reaction is split: some see the downgrade and ongoing stock weakness as evidence of execution risks, while others point to recent earnings and guidance improvements as reasons to buy the dip.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

The proposed Iowa steel plant from Mesabi Metallics is driving concern about future competition and weighing on sentiment, though traders debate whether the projectyears from productionis a meaningful near-term threat. The discussion is also split between worries about Stelcos Hamilton operations being idled amid tariff pressure and optimism around high hot-rolled steel prices, earnings, and a possible POSCO partnership.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention after a sharp, high-volume rally without a clearly identified company announcement. Traders attribute the move to possible short-covering or institutional buying and are speculating about Anktiva catalysts, including FDA label expansion and political attention around the Presidents Cancer Panel; those explanations remain unconfirmed.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScales sharp selloff is being tied to a UBS downgrade and concerns about long construction timelines, limited firm customer commitments, and the path to commercialization. Traders are split between viewing the downgrade as justified given execution risks and treating the decline as a buying opportunity, citing NuScales regulatory approval and potential AI-related power demand.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention after a sharp, volume-backed rebound, with traders focused on Starknets privacy and Bitcoin DeFi push, including strkBTC and STRK20, as well as its post-quantum security narrative. Bulls view these developments as differentiators, while skeptics point to token unlocks and question whether the rally can hold.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

XCN is drawing attention for a recent rebound and traders hopes for a breakout, with bullish commentary tying the projects momentum to Onyxs completed acquisition of Chains technology and its plans for payments, cards, and a neobank. Others remain skeptical, citing weak volume, repeated failed rallies, and concerns that the moves are pump-and-dump activity.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Positive registrational-trial results for Kyvernas miv-cel in stiff person syndrome, alongside durable results in generalized myasthenia gravis, are driving attention as the company advances toward an SPS BLA. Traders are divided between viewing the data as a step toward approval and focusing on the stocks sharp, volatile reaction, with some speculating about profit-taking or a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

Snowflake Stock Jumps Over 21% In Premarket Following Beat-and-Raise Q3: Retail Braces For ‘Parabolic’ Run

Equity

Snowflake CEO Sridhar Ramaswamy said, “Our obsessive drive to produce product cohesion and ease of use has built Snowflake into the easiest and most cost effective enterprise data platform.”


IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

IGM Biosciences Inc

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

IGMS IGM Biosciences Inc